The Cost-Effectiveness of Polar to Zuma in the Front-Line Setting

Polar to Zuma is a CD79B antibody drug conjugate, as we all know. It was initially approved in the relapse setting and combination with BR. And this study is really looking at it in combined with human therapy in the front-line setting. But one of the big questions that comes up is polar ship costs about 209,000 compared to our shop, which is about 79,000. So definitely much more expensive. With about 30,000 new cases of D.O.C.L. every year, incorporating this into the standard practice would lead to significant increase in healthcare expenditures.